Praxis Precision Medicines Inc (PRAX) Stock Price, Quote & News

Company Profile

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance. The company's platforms include cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and solidus to discover and develop antisense oligonucleotide. It also develops Ulixacaltamide, a small molecule inhibitor of T-ty...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 300 8460

Website: praxismedicines.com

Address:

99 High Street, 30th Floor, Boston, United States

Okadarlan Oct. 24 at 5:28 PM

$PRAX 166 in sight

0 · Reply

Mister_Furley_God Oct. 24 at 4:52 PM

$PRAX The puts I bought when this pumped are ALL printing..... And will continue to grow in value.

0 · Reply

CouchPotatoSJW Oct. 24 at 4:31 PM

$PRAX easy money .

0 · Reply

St0ckGuru111 Oct. 24 at 3:46 PM

$PRAX short this trash

0 · Reply

Okadarlan Oct. 24 at 3:28 PM

$PRAX slow chipping still 5 hours left, a dollar per share down.

0 · Reply

FE123 Oct. 24 at 2:35 PM

$SPRB $PRAX $TENX next to $100!!

0 · Reply

Okadarlan Oct. 24 at 1:44 PM

$PRAX Where was all the fake bulls going 200 when it went to 190 during 16 october ? not 1 bull in sight , this will shrug down to 170 today.

0 · Reply

Grreen Oct. 24 at 11:17 AM

$PRAX range holding

0 · Reply

DarkKingTrade Oct. 24 at 10:50 AM

$INBX 100$$$$ 🤌🏻💥💥💥💥 = $PRAX

0 · Reply

Soso777 Oct. 23 at 8:26 PM

Positive results. Can this pull a $PRAX?

0 · Reply

Praxis Precision Medicines, Inc. Announces Pricing of $525 Million Public Offering

Oct 16, 2025, 8:56 PM EDT - 8 days ago

Praxis Precision Medicines, Inc. (PRAX) Discusses Essential3 Topline Results and Next Steps in Essential Tremor Program Transcript

Oct 16, 2025, 4:01 PM EDT - 9 days ago

Praxis Precision Medicines, Inc. Announces Proposed Public Offering

Oct 16, 2025, 2:14 PM EDT - 9 days ago

Praxis Precision's tremor-drug trial succeeds where others have failed. The stock is skyrocketing.

Oct 16, 2025, 12:02 PM EDT - 9 days ago

What's fueling PRAX stock's jaw-dropping 235% surge on Thursday?

Oct 16, 2025, 7:09 AM EDT - 9 days ago

Praxis Precision Medicines' movement disorder drug shows promise in trials

Oct 2, 2025, 4:01 PM EDT - 23 days ago

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 29, 2025, 7:00 AM EDT - 26 days ago

ReCode Therapeutics Announces Over $29 Million in Additional Financing to Advance Genetic Medicines Pipeline and Provides Corporate Update

Sep 4, 2025, 4:01 PM EDT - 7 weeks ago

Praxis Precision Medicines to Participate in September Investor Conferences

Aug 29, 2025, 8:00 AM EDT - 2 months ago

Praxis Precision Medicines to Participate in Upcoming Fireside Chat

Aug 25, 2025, 4:01 PM EDT - 2 months ago

Praxis Medicines to Present at 36th International Epilepsy Congress 2025 in Lisbon, Showcasing Latest RADIANT Study Data and Leading Precision Epilepsy Pipeline

Aug 14, 2025, 9:28 AM EDT - 2 months ago

PRAX Investors Have Opportunity to Join Praxis Precision Medicines, Inc. Fraud Investigation with the Schall Law Firm

Aug 5, 2025, 5:50 PM EDT - 2 months ago

Praxis Precision Medicines, Inc. Investors: Company Investigated by the Portnoy Law Firm

Aug 4, 2025, 12:49 PM EDT - 2 months ago

Praxis Precision Medicines, Inc. (PRAX) Q2 2025 Earnings Call Transcript

Aug 4, 2025, 8:30 AM EDT - 2 months ago

Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Jul 17, 2025, 8:00 AM EDT - 3 months ago

Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Relutrigine for the Treatment of Seizures Associated with SCN2A and SCN8A Developmental and Epileptic Encephalopathies

May 7, 2025, 3:26 PM EDT - 6 months ago

Praxis Precision Medicines 'A Diversified Player In Epilepsy Market,' Analyst Sees Over 100% Stock Upside

May 2, 2025, 8:30 AM EDT - 6 months ago

Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2025 Financial Results

Apr 8, 2025, 8:00 AM EDT - 7 months ago

Praxis Precision Medicines to Hold Virtual Investor Event to Discuss Clinical Programs in Developmental and Epileptic Encephalopathies

Apr 3, 2025, 5:00 PM EDT - 7 months ago

Praxis Precision Medicines to Participate in Upcoming April Conferences

Mar 3, 2025, 11:03 PM EST - 8 months ago

Praxis: A High-Risk, High-Reward Epilepsy Play Post Ulixacaltamide (Rating Upgrade)

Feb 28, 2025, 8:00 AM EST - 8 months ago

Praxis Precision Medicines Provides Update on Essential3 and Corporate Update

Feb 3, 2025, 5:00 PM EST - 9 months ago

Praxis Precision Medicines to Present at Two February Investor Conferences

Jan 12, 2025, 9:00 PM EST - 10 months ago

Praxis Precision Medicines Highlights 2025 Corporate Strategy and Business Priorities

Dec 18, 2024, 8:00 AM EST - 11 months ago

Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted for Relutrigine in Dravet Syndrome

Dec 5, 2024, 8:30 AM EST - 11 months ago

GeneDx to Expand Access to Exome Testing for Pediatric Epilepsy Patients with New Partners

BIIB STOK WGS

Dec 3, 2024, 8:00 AM EST - 11 months ago

Praxis Precision Medicines to Present at Upcoming December Investor Conferences

Nov 6, 2024, 5:00 PM EST - 1 year ago

Praxis Precision Medicines to Participate in Three Upcoming November Investor Conferences

Nov 6, 2024, 11:56 AM EST - 1 year ago

Praxis Precision Medicines, Inc. (PRAX) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 7:30 AM EST - 1 year ago

Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2024 Financial Results

Nov 1, 2024, 8:00 AM EDT - 1 year ago

Praxis Precision Medicines to Announce Third Quarter 2024 Financial Results and Host Conference Call on Wednesday, November 6, 2024

Sep 4, 2024, 8:00 AM EDT - 1 year ago

Praxis Precision Medicines to highlight their Epilepsy Portfolio at the International League Against Epilepsy 15th European Epilepsy Congress with six presentations

Sep 3, 2024, 7:30 AM EDT - 1 year ago

Praxis Precision Medicines announces positive topline results from the EMBOLD study in SCN2A and 8A developmental epilepsies, highlighting the disease-modifying potential of relutrigine

Sep 2, 2024, 5:00 PM EDT - 1 year ago

Praxis Precision Medicines to Announce Topline Data from the Phase 2 EMBOLD Study of Relutrigine (PRAX-562) in SCN2A and SCN8A Developmental and Epileptic Encephalopathies on September 3, 2024

Aug 14, 2024, 3:14 PM EDT - 1 year ago

These Analysts Increase Their Forecasts On Praxis Precision Medicines After Q2 Results

Aug 13, 2024, 2:47 PM EDT - 1 year ago

Praxis Precision Medicines, Inc. (PRAX) Q2 2024 Earnings and Corporate Update Call Transcript

Aug 5, 2024, 4:01 PM EDT - 1 year ago

Praxis Precision Medicines to Announce Second Quarter 2024 Financial Results and Host Conference Call on Tuesday, August 13, 2024

May 17, 2024, 8:00 AM EDT - 1 year ago

Praxis Precision Medicines to Participate in Upcoming Investor Conferences

May 13, 2024, 7:00 AM EDT - 1 year ago

Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2024 Financial Results

May 10, 2024, 8:00 AM EDT - 1 year ago

Praxis Precision Medicines to Report First Quarter 2024 Financial Results on Monday, May 13, 2024

Apr 12, 2024, 8:00 AM EDT - 1 year ago

Praxis Precision Medicines to Present on Ulixacaltamide at the American Academy of Neurology 2024 Annual Meeting

Mar 28, 2024, 12:20 AM EDT - 1 year ago

Praxis Precision Medicines, Inc. Announces Pricing of $200 Million Public Offering

Mar 26, 2024, 1:34 PM EDT - 1 year ago

Praxis: 2nd Half 2024 ET Readout Could Lead To U.S. Regulatory Filing

Mar 26, 2024, 6:30 AM EDT - 1 year ago

Praxis Precision Medicines Reports Positive Results of PRAX-628 Study Evaluating Photo Paroxysmal Response (PPR) Achieving 100% Response in Treated Patients

Mar 25, 2024, 4:01 PM EDT - 1 year ago

Praxis Precision Medicines to Host PRAX-628 Program Update

Mar 5, 2024, 7:00 AM EST - 1 year ago

Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results

Okadarlan Oct. 24 at 5:28 PM

$PRAX 166 in sight

0 · Reply

Mister_Furley_God Oct. 24 at 4:52 PM

$PRAX The puts I bought when this pumped are ALL printing..... And will continue to grow in value.

0 · Reply

CouchPotatoSJW Oct. 24 at 4:31 PM

$PRAX easy money .

0 · Reply

St0ckGuru111 Oct. 24 at 3:46 PM

$PRAX short this trash

0 · Reply

Okadarlan Oct. 24 at 3:28 PM

$PRAX slow chipping still 5 hours left, a dollar per share down.

0 · Reply

FE123 Oct. 24 at 2:35 PM

$SPRB $PRAX $TENX next to $100!!

0 · Reply

Okadarlan Oct. 24 at 1:44 PM

$PRAX Where was all the fake bulls going 200 when it went to 190 during 16 october ? not 1 bull in sight , this will shrug down to 170 today.

0 · Reply

Grreen Oct. 24 at 11:17 AM

$PRAX range holding

0 · Reply

DarkKingTrade Oct. 24 at 10:50 AM

$INBX 100$$$$ 🤌🏻💥💥💥💥 = $PRAX

0 · Reply

Soso777 Oct. 23 at 8:26 PM

Positive results. Can this pull a $PRAX?

0 · Reply

Pegy Oct. 23 at 7:53 PM

$PRAX is this going fly to $250 or will we see $150 next week?

0 · Reply

CouchPotatoSJW Oct. 23 at 5:04 PM

$PRAX the sellers have entered

0 · Reply

Tradeforlosses Oct. 23 at 5:02 PM

$PRAX would this bitch just die already.

1 · Reply

CouchPotatoSJW Oct. 23 at 4:52 PM

$PRAX it comes the drop. Just need to break below $178

0 · Reply

Tradeforlosses Oct. 23 at 4:31 PM

$PRAX Meh this can’t drop because there is no volume. POS stock

0 · Reply

mi_ama_llama Oct. 23 at 4:30 PM

$ITGR $PRAX may make a move like this one did last week.. same amount of tute ownership

0 · Reply

Pegy Oct. 23 at 3:46 PM

$PRAX I’m really curious to see which direction this one will move.

0 · Reply

CouchPotatoSJW Oct. 23 at 3:19 PM

$PRAX this will tank shortly. Absolutely no volume. Adding puts here. $QQQ $SPY

1 · Reply

Okadarlan Oct. 23 at 2:44 PM

$PRAX damn last candle of death is initiated.

0 · Reply

Lovebigruns Oct. 23 at 2:26 PM

$PRAX Why is there no announcement on the offering? I’m surprised the shares haven’t settled around the offering price . Volume is absolutely dead also. Can’t make sense of it all.

1 · Reply

CouchPotatoSJW Oct. 22 at 6:04 PM

$PRAX carpet should get pulled soon . If not today , tomorrow it will

0 · Reply

Okadarlan Oct. 22 at 5:43 PM

$PRAX No more 4 7 -11 dollar ups ? to bad i was adding everytime over 190 , total shares accumlated short 150 .

0 · Reply

Market Cap	3.77B
Revenue (ttm)	8.55M
Net Income (ttm)	-182.82M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-2,138.25%
Debt to Equity Ratio	0.00

Volume	526,700
Avg Vol	822,824
Day's Range	N/A - N/A
Shares Out	21.17M
Stochastic %K	79%
Beta	2.62
Analysts	Strong Sell
Price Target	$288.21